Big Data in Healthcare Market Trends and Forecast Report 2025-2035: By Component, Type of Hardware, Type of Software and Service, Deployment Option, Application Area, Healthcare Vertical, End User, Economic Status, Geography and Leading Players

1.1. RNA Therapeutics and RNA Vaccines Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

5.1. An Overview of Next Generation RNA Therapeutics and Vaccines
5.2. Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
5.3. Types of Next Generation RNA Molecules
5.4. Key Aspects of Next Generation RNA Molecules
5.5. Key Challenges Associated with Traditional RNA Modalities
5.6. Advantages of Using Next Generation RNA Modalities

6.1. RNA Therapeutics and RNA Vaccines: Overall Therapies Landscape
6.1.1. Analysis by Type of Modality
6.1.2. Analysis by Type of Molecule
6.1.3. Analysis by Delivery Vehicle
6.1.4. Analysis by Phase of Development
6.1.5. Analysis by Therapeutic Area
6.1.6. Most Active Players: Analysis by Number of Therapies
6.2. RNA Therapeutics and RNA Vaccines: Clinical Stage Therapies Landscape
6.2.1. Analysis by Phase of Development
6.2.2. Analysis by Route of Administration
6.2.3. Analysis by Therapeutic Area
6.3. RNA Therapeutics and RNA Vaccines: Therapy Developers Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.4. RNA Therapeutics and RNA Vaccines: Circular RNA Therapies Landscape
6.4.1. Analysis by Phase of Development
6.4.2. Analysis by Therapeutic Area
6.4.3. Most Active Players: Analysis by Number of Therapies
6.5. RNA Therapeutics and RNA Vaccines: Self-amplifying RNA Therapies Landscape
6.5.1. Analysis by Phase of Development
6.5.2. Analysis by Therapeutic Area
6.5.3. Most Active Players: Analysis by Number of Therapies

7.1. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technologies Landscape
7.1.1. Analysis by Class of Molecule
7.1.2. Analysis by Type of Molecule
7.1.3. Analysis by Capabilities of the Technology
7.1.4. Analysis by Therapeutic Area
7.1.5. Analysis by Highest Phase of Development
7.2. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technology / Platform Developers Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Operational Model

8.1. Gemcovac
8.1.1. Developer Overview
8.1.2. Drug Overview
8.1.3. Clinical Trial Information
8.1.4. Clinical Trial Endpoints
8.1.5. Clinical Trial Results
8.1.6. Estimated Sales
8.2. ATYR1923
8.2.1. Developer Overview
8.2.2. Drug Overview
8.2.3. Clinical Trial Information
8.2.4. Clinical Trial Endpoints
8.2.5. Clinical Trial Results
8.2.6. Estimated Sales
8.3. ARCT-154
8.3.1. Developer Overview
8.3.2. Drug Overview
8.3.3. Clinical Trial Information
8.3.4. Clinical Trial Endpoints
8.3.5. Clinical Trial Results
8.3.6. Estimated Sales
8.4. GRT-C901
8.4.1. Developer Overview
8.4.2. Drug Overview
8.4.3. Clinical Trial Information
8.4.4. Clinical Trial Endpoints
8.4.5. Clinical Trial Results
8.4.6. Estimated Sales
8.5. VLPCOV-01
8.5.1. Developer Overview
8.5.2. Drug Overview
8.5.3. Estimated Sales
8.6. AVX901
8.6.1. Developer Overview
8.6.2. Drug Overview
8.6.3. Clinical Trial Information
8.6.4. Clinical Trial Endpoints
8.6.5. Clinical Trial Results
8.6.6. Estimated Sales
8.7. MTL-CEBPA + Sorafenib
8.7.1. Developer Overview
8.7.2. Drug Overview
8.7.3. Clinical Trial Information
8.7.4. Clinical Trial Endpoints
8.7.5. Clinical Trial Results
8.7.6. Estimated Sales
8.8. SLATE
8.8.1. Developer Overview
8.8.2. Drug Overview
8.8.3. Clinical Trial Information
8.8.4. Clinical Trial Endpoints
8.8.5. Clinical Trial Results
8.8.6. Estimated Sales

9.1. Analysis Methodology and Key Parameters
9.2. RNA Therapeutics and RNA Vaccines: Clinical Trial Analysis
9.2.1. Analysis by Trial Registration Year
9.2.2. Analysis by Trial Status
9.2.3. Analysis by Trial Registration Year and Trial Status
9.2.4. Analysis by Trial Phase
9.2.5. Analysis by Patients Enrolled
9.2.6. Analysis by Type of Sponsor
9.2.7. Analysis by Therapeutic Area
9.2.8. Analysis by Study Design
9.2.9. Leading Organizations: Analysis by Number of Trials
9.2.10. Analysis by Focus Area
9.2.11. Analysis by Geography

10.1. Analysis Methodology and Key Parameters
10.2. RNA Therapeutics and RNA Vaccines: Patent Analysis
10.2.1. Analysis by Type of Patent
10.2.2. Analysis by Patent Publication Year
10.2.3. Analysis by Patent Jurisdiction
10.2.3.1. Analysis by Patent Jurisdiction: North American Scenario
10.2.3.2. Analysis by Patent Jurisdiction: European Scenario
10.2.3.3. Analysis by Patent Jurisdiction: Asia-Pacific Scenario
10.2.4. Analysis by CPC Symbols
10.2.5. World Cloud Analysis: Emerging Focus Areas
10.2.6. Analysis by Patent Age
10.2.7. Leading Industry Players: Analysis by Number of Patents
10.2.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3. RNA Therapeutics and RNA Vaccines: Patent Benchmarking Analysis
10.4. RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis

11.1. Partnership Models
11.2. RNA Therapeutics and RNA Vaccines: Partnerships and Collaborations
11.2.1. Analysis by Year of Partnership
11.2.2. Analysis by Type of Partnership
11.2.3. Analysis by Year and Type of Partnership
11.2.4. Analysis by Year and Type of Molecule
11.2.5. Analysis by Focus of Partnership
11.2.6. Analysis by Purpose of Partnership
11.2.7. Analysis by Therapeutic Area
11.2.8. Most Active Players: Analysis by Number of Partnerships
11.2.9. Analysis by Geography
11.2.9.1. Local and International Agreements
11.2.9.2. Intracontinental and Intercontinental Agreements

12.1. Types of Funding
12.2. RNA Therapeutics and RNA Vaccines: Funding and Investment Analysis
12.3. Analysis by Year of Funding
12.4. Analysis by Type of Funding
12.5. Analysis by Type of Molecule
12.6. Analysis of Amount Invested by Year of Funding
12.7. Analysis of Amount Invested by Type of Funding
12.8. Analysis by Geography
12.9. Analysis by Year and Type of Funding
12.10. Analysis by Purpose of Funding
12.11. Analysis by Stage of Development
12.12. Analysis by Therapeutic Area
12.13. Most Active Players: Analysis by Number of Funding Instances
12.14. Most Active Players: Analysis by Amount Invested
12.15. Leading Investors: Analysis by Number of Funding Instances

13.1. RNA Therapeutics and RNA Vaccines: Big Pharma Initiatives
13.1.1. Analysis by Number of Initiatives
13.1.2. Analysis by Year of Initiative
13.1.3. Analysis by Type of Initiative
13.1.3.1. Analysis by Type of Partnership
13.1.3.2. Analysis by Type of Funding
13.1.4. Analysis by Purpose of Initiative
13.1.5. Analysis by Year and Number of Initiatives
13.1.6. Analysis by Focus of Initiative
13.1.7. Analysis by Location of Headquarters of Big Pharma Players

14.1. Key Assumptions and Methodology
14.2. Overall RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035)
14.2.1. Scenario Analysis
14.3. Key Market Segmentations
14.4. Dynamic Dashboard

15.1. Therapeutics: Forecasted Estimates (2023-2035)
15.2. Vaccines: Forecasted Estimates (2023-2035)
15.3. Data Triangulation and Validation

16.1. repRNA: Forecasted Estimates (2023-2035)
16.2. saRNA: Forecasted Estimates (2023-2035)
16.3. sacRNA: Forecasted Estimates (2023-2035)
16.4. sa-mRNA: Forecasted Estimates (2023-2035)
16.5. tRNA: Forecasted Estimates (2023-2035)
16.6. Data Triangulation and Validation

17.1. Infectious Diseases: Forecasted Estimates (2023-2035)
17.2. Oncological Disorders: Forecasted Estimates (2023-2035)
17.3. Pulmonary Disorders: Forecasted Estimates (2023-2035)
17.4. Data Triangulation and Validation

18.1. Intradermal Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.2. Intramuscular Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.3. Intravenous Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.4. Data Triangulation and Validation

19.1. North America: Forecasted Estimates (2023-2035)
19.1.1. US: Forecasted Estimates (2023-2035)
19.2. Europe: Forecasted Estimates (2023-2035)
19.2.1. France: Forecasted Estimates (2023-2035)
19.2.2. Italy: Forecasted Estimates (2023-2035)
19.2.3. Spain: Forecasted Estimates (2023-2035)
19.2.4. UK: Forecasted Estimates (2023-2035)
19.2.5. The Netherlands: Forecasted Estimates (2023-2035)
19.3. Asia-Pacific: Forecasted Estimates (2023-2035)
19.3.1. India: Forecasted Estimates (2023-2035)
19.3.2. Japan: Forecasted Estimates (2023-2035)
19.3.3. Singapore: Forecasted Estimates (2023-2035)

Figure 4.1 Executive Summary: Overall Market Landscape
Figure 4.2 Executive Summary: Overall Technology Landscape
Figure 4.3 Executive Summary: Clinical Trial Analysis
Figure 4.4 Executive Summary: Patent Analysis
Figure 4.5 Executive Summary: Partnerships and Collaborations
Figure 4.6 Executive Summary: Funding and Investment Analysis
Figure 4.7 Executive Summary: Big Pharma Initiatives
Figure 4.8 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
Figure 5.2 Key Aspects of Next Generation RNA Molecules
Figure 5.3 Key Challenges Associated with Traditional RNA Modalities
Figure 5.4 Advantages of Using Next Generation RNA Modalities
Figure 6.1 Next Generation RNA Therapies: Distribution by Type of Modality
Figure 6.2 Next Generation RNA Therapies: Distribution by Type of Molecule
Figure 6.3 Next Generation RNA Therapies: Distribution by Delivery Vehicle
Figure 6.4 Next Generation RNA Therapies: Distribution by Phase of Development
Figure 6.5 Next Generation RNA Therapies: Distribution by Therapeutic Area
Figure 6.6 Most Active Players: Distribution by Number of Therapies
Figure 6.7 Clinical Stage Therapies: Distribution by Phase of Development
Figure 6.8 Clinical Stage Therapies: Distribution by Route of Administration
Figure 6.9 Clinical Stage Therapies: Distribution by Therapeutic Area
Figure 6.10 Therapy Developer Landscape: Distribution by Year of Establishment
Figure 6.11 Therapy Developer Landscape: Distribution by Company Size
Figure 6.12 Therapy Developer Landscape: Distribution by Location of Headquarters
Figure 6.13 circRNA Therapies: Distribution by Phase of Development
Figure 6.14 circRNA Therapies: Distribution by Therapeutic Area
Figure 6.15 Most Active Players: Distribution by Number of circRNA Therapies
Figure 6.16 saRNA Therapies: Distribution by Phase of Development
Figure 6.17 saRNA Therapies: Distribution by Therapeutic Area
Figure 6.18 Most Active Players: Distribution by Number of saRNA Therapies
Figure 7.1 Next Generation RNA Technologies: Distribution by Class of Molecule
Figure 7.2 Next Generation RNA Technologies: Distribution by Type of Molecule
Figure 7.3 Next Generation RNA Technologies: Distribution by Capabilities of the Technology
Figure 7.4 Next Generation RNA Technologies: Distribution by Therapeutic Area
Figure 7.5 Next Generation RNA Technologies: Distribution by Highest Phase of Development
Figure 7.6 Technology Developer Landscape: Distribution by Year of Establishment
Figure 7.7 Technology Developer Landscape: Distribution by Company Size
Figure 7.8 Technology Developer Landscape: Distribution by Location of Headquarters
Figure 7.9 Technology Developer Landscape: Distribution by Operational Model
Figure 8.1 Gemcovac®: Estimated Sales
Figure 8.2 ATYR1923: Estimated Sales
Figure 8.3 ARCT-154: Estimated Sales
Figure 8.4 GRT-C901: Estimated Sales
Figure 8.5 VLPCOV-01: Estimated Sales
Figure 8.6 AVX901: Estimated Sales
Figure 8.7 MTL-CEBPA + Sorafenib: Estimated Sales
Figure 8.8 SLATE: Estimated Sales
Figure 9.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2019-2023
Figure 9.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 9.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2019-2022
Figure 9.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 9.5 Clinical Trial Analysis: Distribution by Patients Enrolled
Figure 9.6 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 9.7 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 9.8 Clinical Trial Analysis: Distribution by Study Design
Figure 9.9 Leading Organizations: Distribution by Number of Trials
Figure 9.10 Clinical Trial Analysis: Distribution by Focus Area
Figure 9.11 Clinical Trial Analysis: Distribution by Geography
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Year-wise Trend, 2019-2023
Figure 10.3 Patent Analysis: Distribution by Patent Jurisdiction
Figure 10.4 Patent Jurisdiction: North American Scenario
Figure 10.5 Patent Jurisdiction: European Scenario
Figure 10.6 Patent Jurisdiction: Aisa-Pacific Scenario
Figure 10.7 Patent Analysis: Distribution by Patent Age
Figure 10.8 Patent Analysis: Distribution by CPC Symbols
Figure 10.9 Word Cloud Analysis: Emerging Focus Areas
Figure 10.10 Leading Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.12 Patent Analysis: Distribution by Patent Characteristics
Figure 10.13 RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2019-2023
Figure 11.4 Partnerships and Collaborations: Distribution by Year and Type of Molecule, 2019-2023
Figure 11.5 Partnerships and Collaborations: Distribution by Focus of Partnership
Figure 11.6 Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 11.7 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 11.8 Most Active Players: Distribution by Number of Partnerships
Figure 11.9 Partnerships and Collaborations: Local and International Deals
Figure 11.10 Partnerships andCollaborations: Intercontinental and Intracontinental Deals
Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2019-2023
Figure 12.2 Funding and Investment Analysis: Distribution by Type of Funding
Figure 12.3 Funding and Investment Analysis: Distribution by Type of Molecule
Figure 12.4 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2019-2023 (USD Million)
Figure 12.5 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 12.6 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Figure 12.7 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2019-2023
Figure 12.8 Funding and Investment Analysis: Distribution by Purpose of Funding
Figure 12.9 Funding and Investment Analysis: Distribution by Stage of Development
Figure 12.10 Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 12.11 Most Active Players: Distribution by Number of Funding Instances
Figure 12.12 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 12.13 Leading Investors: Distribution by Number of Funding Instances
Figure 13.1 Big Pharma Initiatives: Distribution by Number of Initiatives
Figure 13.2 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative
Figure 13.3 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 13.4 Big Pharma Initiatives: Cumulative Distribution by Purpose of Initiative
Figure 13.5 Big Pharma Initiatives: Cumulative Year-wise Trend, 2019-2023
Figure 13.6 Big Pharma Initiatives: Distribution by Focus of Initiative
Figure 13.7 Big Pharma Initiatives: Distribution by Location of Headquarters of Big Pharma Players
Figure 14.1 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), BaseScenario (USD Million)
Figure 14.2 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Million)
Figure 14.3 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Million)
Figure 15.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Modality, 2023, 2028 and 2035 (USD Million)
Figure 15.2 Global RNA Therapeutics Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 15.3 Global RNA Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 16.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Molecule, 2023, 2028 and 2035 (USD Million)
Figure 16.2 Global repRNA Therapeutics Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 16.3 Global saRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 16.4 Global sacRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 16.5 Global sa-mRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 16.6 Global tRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 17.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Therapeutic Area, 2023, 2028 and 2035 (USD Million)
Figure 17.2 Global RNA Therapeutics and RNA Vaccines Market for Infectious Diseases, Forecasted Estimates (2023-2035) (USD Million)
Figure 17.3 Global RNA Therapeutics and RNA Vaccines Market for Oncological Disorders, Forecasted Estimates (2023-2035) (USD Million)
Figure 17.4 Global RNA Therapeutics and RNA Vaccines Market for Pulmonary Disorders, Forecasted Estimates (2023-2035) (USD Million)
Figure 18.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Route of Administration, 2023, 2028 and 2035 (USD Million)
Figure 18.2 Global RNA Therapeutics and RNA Vaccines Market for Intradermal Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
Figure 18.3 Global RNA Therapeutics and RNA Vaccines Market for Intramuscular Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
Figure 18.4 Global RNA Therapeutics and RNA Vaccines Market for Intravenous Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Million)
Figure 19.2 RNA Therapeutics and RNA Vaccines Market in North America, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.3 RNA Therapeutics and RNA Vaccines Market in the US, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.4 RNA Therapeutics and RNA Vaccines Market in Europe, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.5 RNA Therapeutics and RNA Vaccines Market in France, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.6 RNA Therapeutics and RNA Vaccines Market in Italy, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.7 RNA Therapeutics and RNA Vaccines Market in Spain, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.8 RNA Therapeutics and RNA Vaccines Market in the UK, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.9 RNA Therapeutics and RNA Vaccines Market in the Netherlands, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.10 RNA Therapeutics and RNA Vaccines Market in Asia-Pacific, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.11 RNA Therapeutics and RNA Vaccines Market in India, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.12 RNA Therapeutics and RNA Vaccines Market in Japan, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.13 RNA Therapeutics and RNA Vaccines Market in Singapore, Forecasted Estimates (2023-2035) (USD Million)
Figure 20.1 RNA Therapeutics and RNA Vaccines Market: Distribution by Leading Players, 2023, 2028 and 2035 (USD Million)

Table 6.1 List of Next Generation RNA Therapeutics and RNA Vaccines
Table 6.2 List of Clinical Stage Next Generation RNA Therapeutics and RNA Vaccines
Table 6.3 List of Next Generation RNA Therapeutic and RNA Vaccine Developers
Table 7.1 List of Next Generation RNA Technologies
Table 7.2 List of Next Generation RNA Technology / Platform Developers
Table 8.1 Gemcovac®: Developer Overview
Table 8.2 Gemcovac®: Drug Overview
Table 8.3 Gemcovac®: Clinical Trial Information
Table 8.4 Gemcovac®: Clinical Trial Endpoints
Table 8.5 Gemcovac®: Clinical Trial Results
Table 8.6 ATYR1923: Developer Overview
Table 8.7 ATYR1923: Drug Overview
Table 8.8 ATYR1923: Clinical Trial Information
Table 8.9 ATYR1923: Clinical Trial Endpoints
Table 8.10 ATYR1923: Clinical Trial Results
Table 8.11 ARCT-154: Developer Overview
Table 8.12 ARCT-154: Drug Overview
Table 8.13 ARCT-154: Clinical Trial Information
Table 8.14 ARCT-154: Clinical Trial Endpoints
Table 8.15 ARCT-154: Clinical Trial Results
Table 8.16 GRT-C901: Developer Overview
Table 8.17 GRT-C901: Drug Overview
Table 8.18 GRT-C901: Clinical Trial Information
Table 8.19 GRT-C901: Clinical Trial Endpoints
Table 8.20 GRT-C901: Clinical Trial Results
Table 8.21 VLPCOV-01: Developer Overview
Table 8.22 VLPCOV-01: Drug Overview
Table 8.23 AVX-901: Developer Overview
Table 8.24 AVX-901: Drug Overview
Table 8.25 AVX-901: Clinical Trial Information
Table 8.26 AVX-901: Clinical Trial Endpoints
Table 8.27 AVX-901: Clinical Trial Results
Table 8.28 MTL-CEBPA + Sorafenib: Developer Overview
Table 8.29 MTL-CEBPA + Sorafenib: Drug Overview
Table 8.30 MTL-CEBPA + Sorafenib: Clinical Trial Information
Table 8.31 MTL-CEBPA + Sorafenib: Clinical Trial Endpoints
Table 8.32 MTL-CEBPA + Sorafenib: Clinical Trial Results
Table 8.33 SLATE: Developer Overview
Table 8.34 SLATE: Drug Overview
Table 8.35 SLATE: Clinical Trial Information
Table 8.36 SLATE: Clinical Trial Endpoints
Table 8.37 SLATE: Clinical Trial Results
Table 9.1 RNA Therapeutics and RNA Vaccines: List of Clinical Trials, Pre-2019-2023
Table 10.1 RNA Therapeutics and RNA Vaccines: List of Filed / Granted Patents, 2019-2023
Table 11.1 RNA Therapeutics and RNA Vaccines: List of Partnerships and Collaborations, 2019-2023
Table 12.1 RNA Therapeutics and RNA Vaccines: List of Funding and Investments, 2019-2023
Table 13.1 RNA Therapeutics and RNA Vaccines: List of Big Pharma Initiatives, 2019-2023
Table 14.1 RNA Therapeutics and RNA Vaccines Market: Expected Launch Year of Forecasted Drug Candidates
Table 22.1 Next Generation RNA Therapies: Distribution by Type of Modality
Table 22.2 Next Generation RNA Therapies: Distribution by Type of Molecule
Table 22.3 Next Generation RNA Therapies: Distribution by Delivery Vehicle
Table 22.4 Next Generation RNA Therapies: Distribution by Phase of Development
Table 22.5 Next Generation RNA Therapies: Distribution by Therapeutic Area
Table 22.6 Most Active Players: Distribution by Number of Therapies
Table 22.7 Clinical Stage Therapies: Distribution by Phase of Development
Table 22.8 Clinical Stage Therapies: Distribution by Route of Administration
Table 22.9 Clinical Stage Therapies: Distribution by Therapeutic Area
Table 22.10 Therapy Developer Landscape: Distribution by Year of Establishment
Table 22.11 Therapy Developer Landscape: Distribution by Company Size
Table 22.12 Therapy Developer Landscape: Distribution by Location of Headquarters
Table 22.13 circRNA Therapies: Distribution by Phase of Development
Table 22.14 circRNA Therapies: Distribution by Therapeutic Area
Table 22.15 Most Active Players: Distribution by Number of circRNA Therapies
Table 22.16 saRNA Therapies: Distribution by Phase of Development
Table 22.17 saRNA Therapies: Distribution by Therapeutic Area
Table 22.18 Most Active Players: Distribution by Number of saRNA Therapies
Table 22.19 Next Generation RNA Technologies: Distribution by Class of Molecule
Table 22.20 Next Generation RNA Technologies: Distribution by Type of Molecule
Table 22.21 Next Generation RNA Technologies: Distribution by Capabilities of the Technology
Table 22.22 Next Generation RNA Technologies: Distribution by Therapeutic Area
Table 22.23 Next Generation RNA Technologies: Distribution by Highest Phase of Development
Table 22.24 Technology Developer Landscape: Distribution by Year of Establishment
Table 22.25 Technology Developer Landscape: Distribution by Company Size
Table 22.26 Technology Developer Landscape: Distribution by Location of Headquarters
Table 22.27 Technology Developer Landscape: Distribution by Operational Model
Table 22.28 Gemcovac®: Estimated Sales
Table 22.29 ATYR1923: Estimated Sales
Table 22.30 ARCT-154: Estimated Sales
Table 22.31 GRT-C901: Estimated Sales
Table 22.32 VLPCOV-01: Estimated Sales
Table 22.33 AVX901: Estimated Sales
Table 22.34 MTL-CEBPA + Sorafenib: Estimated Sales
Table 22.35 SLATE: Estimated Sales
Table 22.36 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2019-2023
Table 22.37 Clinical Trial Analysis: Distribution by Trial Status
Table 22.38 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2019-2022
Table 22.39 Clinical Trial Analysis: Distribution by Trial Phase
Table 22.40 Clinical Trial Analysis: Distribution by Patients Enrolled
Table 22.41 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 22.42 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 22.43 Clinical Trial Analysis: Distribution by Study Design
Table 22.44 Leading Organizations: Distribution by Number of Trials
Table 22.45 Clinical Trial Analysis: Distribution by Focus Area
Table 22.46 Clinical Trial Analysis: Distribution by Geography
Table 22.47 Patent Analysis: Distribution by Type of Patent
Table 22.48 Patent Analysis: Cumulative Year-wise Trend, 2019-2023
Table 22.49 Patent Analysis: Distribution by Patent Jurisdiction
Table 22.50 Patent Jurisdiction: North American Scenario
Table 22.51 Patent Jurisdiction: European Scenario
Table 22.52 Patent Jurisdiction: Aisa-Pacific Scenario
Table 22.53 Patent Analysis: Distribution by Patent Age
Table 22.54 Patent Analysis: Distribution by CPC Symbols
Table 22.55 Leading Industry Players: Distribution by Number of Patents
Table 22.56 Leading Non-Industry Players: Distribution by Number of Patents
Table 22.57 Patent Analysis: Distribution by Patent Characteristics
Table 22.58 RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis
Table 22.59 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Table 22.60 Partnerships and Collaborations: Distribution by Type of Partnership
Table 22.61 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2019-2023
Table 22.62 Partnerships and Collaborations: Distribution by Year and Type of Molecule, 2019-2023
Table 22.63 Partnerships and Collaborations: Distribution by Focus of Partnership
Table 22.64 Partnerships and Collaborations: Distribution by Purpose of Partnership
Table 22.65 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 22.66 Most Active Players: Distribution by Number of Partnerships
Table 22.67 Partnerships and Collaborations: Local and International Deals
Table 22.68 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 22.69 Funding and Investment Analysis: Cumulative Year-wise Trend, 2019-2023
Table 22.70 Funding and Investment Analysis: Distribution by Type of Funding
Table 22.71 Funding and Investment Analysis: Distribution by Type of Molecule
Table 22.72 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2019-2023 (USD Million)
Table 22.73 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 22.74 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Table 22.75 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2019-2023
Table 22.76 Funding and Investment Analysis: Distribution by Purpose of Funding
Table 22.77 Funding and Investment Analysis: Distribution by Stage of Development
Table 22.78 Funding and Investment Analysis: Distribution by Therapeutic Area
Table 22.79 Most Active Players: Distribution by Number of Funding Instances
Table 22.80 Most Active Players: Distribution by Amount Invested (USD Million)
Table 22.81 Leading Investors: Distribution by Number of Funding Instances
Table 22.82 Big Pharma Initiatives: Distribution by Number of Initiatives
Table 22.83 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative, 2019-2023
Table 22.84 Big Pharma Initiatives: Distribution by Type of Initiative
Table 22.85 Big Pharma Initiatives: Cumulative Distribution by Purpose of Initiative
Table 22.86 Big Pharma Initiatives: Cumulative Year-wise Trend, 2019-2023
Table 22.87 Big Pharma Initiatives: Distribution by Focus of Initiative
Table 22.88 Big Pharma Initiatives: Distribution by Location of Headquarters of Big Pharma Players
Table 22.89 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Base Scenario (USD Million)
Table 22.90 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Million)
Table 22.91 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Million)
Table 22.92 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Modality, 2023, 2028 and 2035 (USD Million)
Table 22.93 Global RNA Therapeutics Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.94 Global RNA Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.95 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Molecule, 2023, 2028 and 2035 (USD Million)
Table 22.96 Global repRNA Therapeutics Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.97 Global saRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.98 Global sacRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.99 Global sa-mRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.100 Global tRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.101 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Therapeutic Area, 2023, 2028 and 2035 (USD Million)
Table 22.102 Global RNA Therapeutics and RNA Vaccines Market for Infectious Diseases, Forecasted Estimates (2023-2035) (USD Million)
Table 22.103 Global RNA Therapeutics and RNA Vaccines Market for Oncological Disorders, Forecasted Estimates (2023-2035) (USD Million)
Table 22.104 Global RNA Therapeutics and RNA Vaccines Market for Pulmonary Disorders, Forecasted Estimates (2023-2035) (USD Million)
Table 22.105 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Route of Administration, 2023, 2028 and 2035 (USD Million)
Table 22.106 Global RNA Therapeutics and RNA Vaccines Market for Intradermal Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
Table 22.107 Global RNA Therapeutics and RNA Vaccines Market for Intramuscular Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
Table 22.108 Global RNA Therapeutics and RNA Vaccines Market for Intravenous Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
Table 22.109 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Million)
Table 22.110 RNA Therapeutics and RNA Vaccines Market in North America, Forecasted Estimates (2023-2035) (USD Million)
Table 22.111 RNA Therapeutics and RNA Vaccines Market in the US, Forecasted Estimates (2023-2035) (USD Million)
Table 22.112 RNA Therapeutics and RNA Vaccines Market in Europe, Forecasted Estimates (2023-2035) (USD Million)
Table 22.113 RNA Therapeutics and RNA Vaccines Market in France, Forecasted Estimates (2023-2035) (USD Million)
Table 22.114 RNA Therapeutics and RNA Vaccines Market in Italy, Forecasted Estimates (2023-2035) (USD Million)
Table 22.115 RNA Therapeutics and RNA Vaccines Market in Spain, Forecasted Estimates (2023-2035) (USD Million)
Table 22.116 RNA Therapeutics and RNA Vaccines Market in the UK, Forecasted Estimates (2023-2035) (USD Million)
Table 22.117 RNA Therapeutics and RNA Vaccines Market in the Netherlands, Forecasted Estimates (2023-2035) (USD Million)
Table 22.118 RNA Therapeutics and RNA Vaccines Market in Asia-Pacific, Forecasted Estimates (2023-2035) (USD Million)
Table 22.119 RNA Therapeutics and RNA Vaccines Market in India, Forecasted Estimates (2023-2035) (USD Million)
Table 22.120 RNA Therapeutics and RNA Vaccines Market in Japan, Forecasted Estimates (2023-2035) (USD Million)
Table 22.121 RNA Therapeutics and RNA Vaccines Market in Singapore, Forecasted Estimates (2023-2035) (USD Million)
Table 22.122 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Leading Players, 2023, 2028 and 2035 (USD Million)